Compare Amphastar Pharmaceuticals Inc (AMPH) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while TotalEnergies SE trades at $79.64 (market cap $173.13B). The key difference: TotalEnergies SE is far larger — about 209.6× Amphastar Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 5.37% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TTE | |
|---|---|---|
Market Cap | $826.08M | $173.13B |
Sector | Health | Energy |
52-Week High | $30.81 | $93.60 |
52-Week Low | $16.87 | $57.39 |
Enterprise Value | $1.22B | $207.27B |
Dividend Yield | — | 5.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
TTE trades at $78.5, up 0.35% today, with a neutral technical signal and mixed earnings history including a Q1 2026 beat. Valuation ratios appear attractive with a P/E of 11.65 and EV/EBITDA of 4.81. Recent news highlights strategic divestments and new LNG shipments, while cash flow trends show stabilization after recent declines.
Outlook is cautiously positive given strong analyst buy ratings (57.58%) and shareholder returns via dividends, but risks include revenue declines, geopolitical exposure, and regulatory pressures. The stock offers value characteristics with moderate growth prospects amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
